The cost effectiveness of influenza vaccination for adults aged 50 to 64 years:: A model-based analysis for Spain

被引:25
作者
Aballea, Samuel
De Juanes, Jose Ramon
Barbieri, Marco
Martin, Monique
Chancellor, Jeremy
Oyagueez, Itziar
Verwee, Bertrand
Largeron, Nathalie
机构
[1] I3 Innovus, Uxbridge UB8 1QG, Middx, England
[2] Hosp 12 Octubre, E-28041 Madrid, Spain
[3] Univ Pompeu Fabra, Barcelona, Spain
[4] Sanofi Pasteur MSD, Madrid, Spain
[5] Sanofi Pasteur, Lyon, France
关键词
influenza; cost effectiveness; Spain;
D O I
10.1016/j.vaccine.2007.07.033
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
An economic evaluation of reducing the age threshold for routine influenza vaccination in Spain from 65 to 50 years was performed. A probabilistic model was used to compare a policy based on a recommendation to vaccinate all adults aged 50-64 with the existing vaccination policy for that age group, during interpandemic periods. Two perspectives were considered: third-party payer (TPP) and societal. Model inputs were obtained primarily from the published literature and validated through expert opinion. From TPP perspective, incremental costeffectiveness ratios were estimated at E 14,919 per quality-adjusted life-year (QALY) gained and is an element of 9731 per life-year gained. From societal perspective, the corresponding results were 464149 per QALY and is an element of 2706 per life-year gained. Extending routine influenza vaccination to people over 50 years of age is likely to be cost-effective. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6900 / 6910
页数:11
相关论文
共 46 条
[41]   The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age [J].
Turner, DA ;
Wailoo, AJ ;
Cooper, NJ ;
Sutton, AJ ;
Abrams, KR ;
Nicholson, KG .
VACCINE, 2006, 24 (07) :1035-1043
[42]  
Uphoff H, 2003, Euro Surveill, V8, P156
[43]  
*VAD INT, 2005, ESP FARM BIOL
[44]   Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries [J].
van Essen, GA ;
Palache, AM ;
Forleo, E ;
Fedson, DS .
VACCINE, 2003, 21 (16) :1780-1785
[45]  
Zimmerman RK, 1999, AM FAM PHYSICIAN, V60, P2061
[46]  
2003, MMWR MORB MORTAL WKL, V52, P987